Cited by

• Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine.

  Fuksiewicz M, Kowalska M, Kolasinska-Cwikla A, Kotowicz B. Fuksiewicz M, et al. Endocr Connect. 2022 Aug 22;11(9):e210647. doi: 10.1530/EC-21-0647. Print 2022 Sep 1. Endocr Connect. 2022. PMID: 35900770 Free PMC article.
• The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC).

  van Veenendaal LM, Bertolli E, Korse CM, Klop WMC, Tesselaar MET, van Akkooi ACJ. van Veenendaal LM, et al. Ann Surg Oncol. 2021 Feb;28(2):1019-1028. doi: 10.1245/s10434-020-08656-7. Epub 2020 Jun 11. Ann Surg Oncol. 2021. PMID: 32529274
• Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors.

  Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Li Y, et al. Front Oncol. 2021 May 24;11:681149. doi: 10.3389/fonc.2021.681149. eCollection 2021. Front Oncol. 2021. PMID: 34109127 Free PMC article.
• Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

  Zou J, Li Q, Kou F, Zhu Y, Lu M, Li J, Lu Z, Shen L. Zou J, et al. Curr Oncol. 2019 Feb;26(1):e30-e38. doi: 10.3747/co.26.4135. Epub 2019 Feb 1. Curr Oncol. 2019. PMID: 30853807 Free PMC article.
• Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

  Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Bocchini M, et al. Front Oncol. 2020 May 27;10:831. doi: 10.3389/fonc.2020.00831. eCollection 2020. Front Oncol. 2020. PMID: 32537434 Free PMC article. Review.